CIIT vs REGN · rev $9.3M vs P/E 14, rev $14.34B
Tianci International, Inc. Common Stock (CIIT) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Tianci International, Inc. Common Stock (CIIT) is a integrated freight & logistics company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported CIIT revenue for 2025-07-31 was $9.3M. Net income was -$2.7M. Revenue was up 7.7% from 2024-07-31 to 2025-07-31. CIIT currently screens at market cap $2.1M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
CIIT currently screens at market cap $2.1M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the CIIT and REGN stock pages for the full models.
Not investment advice.